| Literature DB >> 26815035 |
Furong Li1, Bo Gao1, Wei Xu2, Ling Chen3, Sidong Xiong1,2.
Abstract
BACKGROUND: Tuberculosis (TB) represents a major global health problem. The prognosis of clinically active tuberculosis depends on the complex interactions between Mycobacterium tuberculosis (Mtb) and its host. In recent years, autophagy receives particular attention for its role in host defense against intracellular pathogens, including Mtb. In present study, we aim to investigate the relationship of autophagy induction by clinical isolates of Mtb with the clinical outcomes in patients with TB. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2016 PMID: 26815035 PMCID: PMC4729487 DOI: 10.1371/journal.pone.0147810
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Clinical isolates of Mtb could induce autophagy in macrophages.
(A) THP-1 were infected with H37Rv and two clinical isolates of Mtb (M1 and M2) (MOI = 10) for 4 hr in the absence or presence of Baf A1. Cells were harvested and subjected to western blot analysis using anti-LC3. The expression of GAPDH was used as a loading control. The immunoblots were scanned and subjected to densitometric analysis. LC3-II/GAPDH ratio was calculated, and the mean value of at least five samples from three independent experiments was shown at the bottom of each lane. (B) THP-1 were infected with clinical Mtb isolates (M1, M2) or H37Rv (MOI = 10) for 4 hr. Cells were harvested and subjected to western blot analysis using antibodies against p62 and GAPDH. Protein was quantitified by densitometry. P62/GAPDH ratio was calculated, and the mean value of at least five samples from three independent experiments was shown at the bottom of each lane. (C and D) RAW264.7 and BMDMs macrophages were treated as in B. Cells were harvested and subjected to western blot analysis using antibodies against p62 and GAPDH. Protein was quantitified by densitometry. LC3-II/GAPDH or p62/GAPDH ratio was calculated, respectively, and the mean value of at least five samples from three independent experiments was shown at the bottom of each lane. (E) THP-1 macrophages were infected with a clinical isolates of Mtb (MOI = 10) for 4 h. Cells were then incubated sequentially with anti-LC3B antibody and TRITC goat anti-rabbit IgG (red), followed by the staining with DAPI to visualize the nuclei (blue), the right panel was the quantification of LC3 punctuate per cell. The data shown represent mean ± SE from three independent experiments.
Fig 2Different clinical isolates of Mtb induced autophagy in THP-1 cells to a different extent.
(A) THP-1 cells were infected with clinical isolates of Mtb for 4 hr. Cells were harvested and subjected to western blot analysis using anti-LC3. GAPDH was used as a loading control. Representative immunoblots (sample 1–7, 13–19, 40–50, 73–80, 112–122, 155–165) were shown. The immunoblots were scanned and subjected to densitometric analysis. LC3-II/GAPDH ratio was calculated, and the mean value of at least five samples from three independent experiments was shown at the bottom of each lane. (B) The extent of autophagosome formation was graded on LC3-II/GAPDH ratio into four classes: absent (0–0.25), weak (0.26–0.50), moderate (0.51–0.75), and strong (>0.75).
Characteristics of patients harboring clinical Mtb isolates with different autophagy-inducing ability.
| Variable | Autophagosome formation | |||||
|---|---|---|---|---|---|---|
| Total | Absent | Weak | Moderate | Strong | ||
| N = 185 n (%) | N = 47 n (%) | N = 43 n (%) | N = 47 n (%) | N = 48 n (%) | ||
| Male | 106 (57.3) | 21 (44.7) | 25 (58.1) | 33 (70.0) | 27 (57.3) | |
| Female | 79 (42.7) | 26 (55.3) | 18 (61.9) | 14 (30.0) | 21 (42.7) | |
| <30 | 40 (21.6) | 11 (23.4) | 14 (32.6) | 8 (17.0) | 7 (14.6) | |
| 30–50 | 88 (47.6) | 21 (44.7) | 16 (37.2) | 27 (57.4) | 24 (50.0) | |
| >50 | 57 (30.8) | 15 (31.9) | 13 (30.2) | 12 (25.6) | 17 (35.4) | |
| Yes | 86 (46.5) | 27 (57.4) | 22 (51.2) | 20 (42.6) | 17 (35.4) | |
| No | 99 (53.5) | 20 (42.6) | 21 (48.8) | 27 (57.4) | 31 (64.6) | |
| Yes | 91 (49.2) | 25 (53.2) | 18 (41.9) | 24 (51.1) | 27 (56.3) | |
| No | 94 (50.8) | 22 (46.8) | 25 (58.1) | 23 (48.9) | 21 (43.7) | |
| PTB alone | 131 (70.8) | 35 (74.5) | 28 (65.1) | 32 (68.1) | 36 (75.0) | |
| EPTB alone | 8 (4.3) | 1 (2.1) | 2 (4.7) | 3 (6.4) | 2 (4.2) | |
| PTB+EPTB | 46 (24.9) | 11 (23.4) | 13 (30.2) | 12 (25.5) | 10 (20.8) | |
| Minimal | 53 (28.6) | 7 (14.9) | 9 (20.9) | 16 (34.0) | 21 (43.8) | |
| Moderate-advanced | 70 (37.8) | 14 (29.8) | 16 (37.2) | 21 (44.7) | 19 (39.6) | |
| Far-advanced | 62 (33.6) | 26 (55.3) | 18 (41.9) | 10 (21.3) | 8 (16.6) | |
| 129.4±18.3 | 128.2±16.3 | 132.6±18.4 | 126.8±17.9 | 130.3±20.5 | ||
| 7.8±2.7 | 7.1±2.4 | 8.15±2.5 | 8.3±3.1 | 7.6±2.6 | ||
| 48.2±21.4 | 48.5±20.8 | 49.0±20.4 | 49.3±21.4 | 45.9±23.1 | ||
| 24.9±3.5 | 25.2±3.3 | 24.8±3.7 | 24.6±3.5 | 25.3±3.7 | ||
| New | 99 (53.5) | 12 (25.5) | 17(39.5) | 31 (66.0) | 37 (77.1 | |
| Re-treatment | 86 (46.5) | 35 (74.5) | 26(60.5) | 16 (34.0) | 11 (22.9) | |
| Favourable | 145 (78.4) | 29 (61.7) | 30 (69.8) | 40 (85.1) | 46 (95.8) | |
| Unfavourable | 40 (21.6) | 18 (38.3) | 13 (30.2) | 7 (14.9) | 2 (4.2) | |
Abbreviation: PTB, pulmonary tuberculosis; EPTB, extra-pulmonary tuberculosis; ESR, erythrocyte sedimentation rate; CO2CP, Carbon Dioxide Combining Power
aChi-square test
bOne way ANOVA.
Univariate and multivariate logistic regression analysis of far-advanced radiographic disease in TB patients*.
| Variable | Radiographic finding | ||||
|---|---|---|---|---|---|
| Far-advanced | Univariate analysis | Multivariate Analysis | |||
| All | n | % | OR (95%CI), | aOR (95%CI), | |
| Strong | 48 | 8 | 16.7 | Reference | Reference |
| Moderate | 47 | 10 | 21.3 | 1.351 (0.48–3.79), 0.567 | 1.303 (0.46–3.72), 0.621 |
| Absent-Low | 90 | 43 | 47.8 | 4.574 (1.93–10.86), 0.001 | 4.710 (1.93–11.50), 0.001 |
| Female | 79 | 25 | 31.7 | Reference | |
| Male | 106 | 36 | 34 | 1.005 (0.54–1.87), 0.988 | |
| <30 | 40 | 10 | 25 | Reference | Reference |
| 30–50 | 88 | 28 | 31.8 | 1.400 (0.60–3.26), 0.435 | 2.089 (0.85–5.16), 0.110 |
| >50 | 57 | 23 | 40.4 | 2.029 (0.83–4.94), 0.119 | 2.915(1.12–7.58), 0.028 |
| No | 94 | 33 | 35.1 | Reference | |
| Yes | 91 | 28 | 30.8 | 0.822 (0.44–1.52), 0.531 | |
| No | 99 | 28 | 28.3 | Reference | Reference |
| Yes | 86 | 33 | 38.4 | 1.579 (0.85–2.93), 0.147 | 1.381 (0.71–2.69), 0.344 |
| PTB alone | 131 | 45 | 34.4 | Reference | |
| PTB+EPTB | 46 | 16 | 34.8 | 1.019 (0.50–2.07), 0.958 | |
| ≤10.0 | 152 | 50 | 32.9 | Reference | |
| >10.0 | 33 | 11 | 33.3 | 0.980 (0.44–2.18), 0.961 | |
| ≤40 | 77 | 21 | 27.3 | Reference | Reference |
| >40 | 108 | 40 | 37 | 1.569 (0.83–2.96), 0.165 | 1.609 (0.81–3.19), 0.174 |
Abbreviation: OR, odd ratio; aOR, adjusted OR; CI, confidence interval
*For the regression analysis of radiographic findings, the radiographic extent of disease was categorized into two group: Minimal to moderate-advanced group and Far-advanced group.
Univariate and multivariate logistic regression analysis of treatment outcomes in TB patients.
| Variable | Treatment outcome | ||||
|---|---|---|---|---|---|
| Unfavorable | Univariate analysis | Multivariate Analysis | |||
| All | n | % | OR (95%CI), | aOR (95%CI), | |
| Strong | 48 | 3 | 6.3 | Reference | Reference |
| Moderate | 47 | 7 | 14.9 | 2.625 (0.64–10.84), 0.182 | 2.412 (0.57–10.30), 0.235 |
| Absent-Low | 90 | 31 | 34.4 | 7.881 (2.27–27.43), 0.001 | 8.024 (2.22–28.97), 0.001 |
| Female | 79 | 15 | 19 | Reference | |
| Male | 106 | 26 | 24.5 | 1.387 (0.68–2.84), 0.371 | |
| <30 | 40 | 5 | 12.5 | Reference | Reference |
| 30–50 | 88 | 19 | 21.6 | 1.928 (0.66–5.60), 0.228 | 2.730 (0.88–8.48), 0.083 |
| >50 | 57 | 14 | 24.6 | 2.975 (0.99–8.90), 0.051 | 4.274 (1.32–13.86), 0.015 |
| No | 94 | 19 | 20.2 | Reference | |
| Yes | 91 | 22 | 24.2 | 1.259 (0.63–2.52), 0.517 | |
| No | 99 | 18 | 18.2 | Reference | Reference |
| Yes | 86 | 23 | 26.7 | 1.643 (0.82–3.31), 0.164 | 1.616 (0.73–3.57), 0.318 |
| PTB alone | 131 | 22 | 16.8 | Reference | Reference |
| EPTB alone | 8 | 2 | 25 | 1.585 (0.30–8.25), 0.597 | 2.003 (0.29–12.85), 0.494 |
| PTB+EPTB | 46 | 16 | 34.8 | 2.504 (1.18–5.33), 0.017 | 2.525 (1.09–5.85), 0.031 |
| ≤10.0 | 152 | 32 | 21.1 | Reference | |
| >10.0 | 33 | 9 | 27.3 | 1.406 (0.60–3.32), 0.437 | |
| ≤40 | 77 | 12 | 15.6 | Reference | Reference |
| >40 | 108 | 29 | 26.9 | 1.99 (0.94–4.20), 0.072 | 2.104 (0.92–4.80), 0.077 |
Abbreviation: PTB, pulmonary tuberculosis; EPTB, extra-pulmonary tuberculosis; OR, odd ratio; aOR, adjusted OR; CI, confidence interval.